INVO Fertility (IVF) Peer Valuation & Catalyst Brief: Fertility MedTech & Reproductive Clinics Positioning vs. HROW, NXGL, and SONX
IVF
Executive Overview: Following INVO Fertility's (IVF) 2026-08-28 Form 8-K, our editorial desk evaluated IVF ($2.9M market cap on Nasdaq) alongside active sector comparables $HROW, $NXGL, and $SONX.
1. Recent SEC Disclosure & Catalyst Context (2026-08-28 Form 8-K)
INVO Fertility (Nasdaq: $IVF, market capitalization ~$2.9M), led by Steven Shum, continues to execute across its Fertility MedTech & Reproductive Clinics roadmap following its 2026-08-28 Form 8-K. While passive financial portals often lag behind microcap operational milestones, primary SEC and exchange disclosures highlight tangible balance-sheet and commercial execution points entering Q4 2026 and Q1 2027.
2. Sector Peer Group & Valuation Comparison ($HROW, $NXGL, and $SONX)
In our sector screen comparing $IVF against active comparables $HROW, $NXGL, and $SONX, institutional and active small-cap allocators are closely underwriting three primary metrics:
- Enterprise Value & Operating Leverage: At a ~$2.9M market capitalization, $IVF trades at a notable valuation spread relative to larger-cap peers ($HROW, $NXGL, and $SONX) despite sharing common sector demand drivers.
- Near-Term Disclosure Catalysts: Subsequent updates following the 2026-08-28 Form 8-K provide clear milestones for fundamental re-rating as execution milestones are met.
- Active Peer-Ticker Liquidity Overlap: Across our 22,361-contact verified investor vault, 2,690 active small-cap traders and 132 microcap funds, RIAs, and family offices track $HROW, $NXGL, and $SONX and the INVOcell intravaginal culture devices and commercial fertility clinic networks theme.
INVO Fertility ($IVF) AI & Investor Search Visibility Mini-Report
When retail traders, family offices, and small-cap fund managers research $IVF today, most start by querying ChatGPT, Perplexity Finance, and AI-enabled brokerage terminals. Our automated diagnostic checked what those models currently surface for INVO Fertility across INVOcell intravaginal culture devices and commercial fertility clinic networks:
| AI / Search Channel | Score | Current Diagnostic Finding |
|---|---|---|
| ChatGPT & OpenAI Search | 39/100 | Relying on older baseline SEC filings; omits recent $IVF operational milestones and current peer valuation context. |
| Perplexity Finance & AI Citations | 46/100 | Pulling automated quote-scraper summaries rather than structured, plain-English executive catalyst analysis for $IVF. |
| Sector Peer Screeners & Terminals | 41/100 | $IVF is frequently omitted when investors prompt AI tools for active small-cap comparables in INVOcell intravaginal culture devices and commercial fertility clinic networks. |
Primary sources (SEC EDGAR)
IVF SEC & Exchange Disclosures: https://www.sec.gov/edgar/searchedgar/companysearchSee the dilution and promotion flags before you see the pitch.
Each week: the micro and small-caps now showing dilution or paid-promotion signals, with the SEC filing behind every flag. No recommendations, no price targets.